Australia: Proposed Changes To The TGA Regulatory Framework For Biologicals – Capturing Autologous Cell Therapies Wihtin The ARTG

Last Updated: 17 May 2018
Article by Sally J. Davis, Michael Caine and Alex Tzanidis

The Therapeutic Goods Administration (TGA) has recently announced changes to the biologicals regulatory framework to introduce regulatory requirements around autologous human cell and tissue therapies, including stem cells. The proposed changes, expected to take effect from 1 July 2018, will bring the Australian regulatory framework into better conformity with corresponding US and European law, offering greater certainty to pharmaceutical companies developing autologous cell therapies.  The proposed changes also aim to protect consumers from off-clinical trial use of experimental therapies. From a commercial perspective, the inclusion of autologous human cell and tissue therapies on the Australian Register of Therapeutic Goods (ARTG) should also provide for patent term extensions.

Human autologous cell and tissue therapy

Autologous cell and tissue therapy requires cells and/or tissue to be removed from, and then reinfused or applied to, the patent. Examples of autologous cell and tissue products include blood and blood components (i.e., erythrocytes, plasma, serum, platelets and platelet-rich plasma), skin grafts, bone grafts, genetically modified lymphocytes (e.g. CAR-T cells) and stem cells.

Under current law (Therapeutic Goods (Excluded Goods) Order No. 1 of 2011), certain categories of autologous human cell and tissue products are not considered therapeutic goods and can therefore be supplied without approval by the TGA. They include human autologous cells and tissue that are:

  1. Collected from a patient who is under the clinical care and treatment of a medical practitioner registered under a law of a State or an internal Territory; and
  2. Manufactured by a medical practitioner, or by a person or persons under the professional supervision of that medical practitioner; and
  3. For therapeutic application in the treatment of a single indication and in a single course of treatment of a patient by the same medical practitioner, or by a person or persons under the professional supervision of the same medical practitioner.

These exclusions were largely motivated by the limited application of human autologous cell and tissue therapies at the time the Order was made. The use of human autologous cells and tissues had also been restricted to either unmodified or minimally modified cells in well established procedures with proven safety and efficacy.

More recently, the industry has seen a growth of autologous cell and tissue therapies for a broad range of indications. In the context of stem cell therapies, the limited regulation in Australia has allowed for the emergence of direct-to-consumer therapeutic services based on little-to-no peer-reviewed evidence or clinical trial data to establish efficacy. Currently, there are a number of clinics throughout Australia that are offering stem cell therapies outside of clinical trials for the treatment of osteoarthritis and muscular pain, infertility, sports injuries, cancers, muscular dystrophy, multiple sclerosis, stroke and cosmetic application, such as facial rejuvenation and other anti-aging therapies. In addition, development in ex vivo cell culture and expansion technology has facilitated greater manipulation of cells, which increases the risks associated with patient response and safety, in addition to cell handling and manufacturing risks that may impact on product potency, purity, identity, traceability, safety and stability.

The increased risks associated with human autologous cell and tissue products prompted the TGA to conduct a comprehensive review of the biologicals regulatory framework to ensure that human autologous cell and tissue products are properly regulated in Australia. Similar reviews have previously been conducted by the FDA and the European Medicines Agency, which resulted in the regulation of human autologous cells and tissues, such as human cells, tissue, and cellular and tissue-based products (HCT/Ps) in the US and advanced therapy medicinal products (ATMPs) in Europe. As a result of these changes, a number of human autologous cell and tissue therapies are now registered in the US and Europe. The introduction of similar requirements for the regulation of human autologous cell and tissue products in Australia should provide more certainty and consistency for pharmaceutical companies looking to enter the Australian market.

Proposed regulation of human autologous cell and tissue products by the TGA

The proposed regulatory changes to the TGA's biologicals regulatory framework were recently reported by Penny Field of Bioregulatory Consulting (article available here).  As noted in Penny's article, the proposed changes seek to clarify the type of human autologous cell and tissue products that are to be (i) excluded from regulation by the TGA, (ii) exempt from some regulatory requirements or (iii) fully regulated by the TGA. 

Given the strict definitions associated under the revised guidelines, it is likely that a vast majority of human autologous cell and tissue products currently in use will be fully regulated by the TGA as biologicals. The Therapeutic Goods Regulations 1990 classifies biologicals based upon the level of modification or manipulation that the products are subject to and how closely their intended use matches their original biological function.  For instance, Class 1 and 2 biologicals are minimally manipulated (e.g., centrifugation, washing, refrigeration, freezing, etc.) for homologous use. Class 3 biologicals are prepared using more complex methods, such as enzymatic dissociation, without altering the inherent biological properties of the product (e.g., demineralised bone, cultured fibroblasts for skin repair and mesenchymal stem cells for the treatment of graft-versus-host disease). Class 4 biologicals are high-risk, typically prepared using complex biological manipulation, such as genetic modification, that alter the properties of the product (e.g., genetically modified dermal fibroblasts for the treatment of muscular dystrophy, CAR-T cells, iPSCs).

Each of the products falling within these classes must comply with all applicable standards, reporting requirements for adverse events, conditions relating to records and reporting, advertising restriction, registration on the ARTG and manufacturing licencing or certification requirements. When the proposed changes come into effect, human autologous cell and tissue products that were not previously subject to these regulations will be required to conform to the new requirements.

Patent term extension for autologous cell and tissue products

Under Australian law, a patent term extension of up to 5 years is available for a granted patent where one or more pharmaceutical substances per se (or pharmaceutical substances produced by recombinant DNA technology) are disclosed in the specification and in substance fall within the scope of the claim or claims of that patent.  In addition, goods containing, or consisting of, the pharmaceutical substance must be included in the ARTG and the period beginning on the date of the patent and ending on the first regulatory approval date for the substance must be at least five years.

For the purposes of patent term extension, a pharmaceutical substance includes "a substance (including a mixture or compound of substances) for therapeutic use whose application (or one of whose applications) involves a chemical interaction, or physicochemical interaction, with a human physiological system."  It is expected that human autologous cell and tissue products would to satisfy this requirement, insofar as they are "for therapeutic use whose application (or one of whose applications) involves a chemical interaction, or physicochemical interaction, with a human physiological system". 

For these reasons, the proposed regulatory changes to the TGA's biologicals regulatory framework, as outlined above, should pave the way for patent term extensions for eligible claims that are directed to human autologous cell and tissue products and where such products are included on the ARTG.  


The TGA expects the proposed regulatory changes to its biologicals regulatory framework to come into effect on 1 July 2018. 

The proposed regulation of human autologous cell and tissue products represents an important step in ensuring that Australian consumers are protected from the increased risks associated with the use of such products, in particular those that have not been subjected to rigorous clinical testing for efficacy and safety. The proposed regulatory changes will also bring Australia into better conformity with the US and Europe. Harmonisation of regulatory requirements for pharmaceutical products allows for greater consistency in the approach taken to obtaining regulatory approval in key jurisdictions. The registration of pharmaceutical products on the ARTG is also likely to provide an opportunity for patent holders to secure patent term extensions for up to five years. 

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions